Demonstrates survival gains and cost savings in cancer patients, indicating significant health benefits.
PURPOSE Continued smoking after a cancer diagnosis worsens survival and increases health care costs. We projected the 10-year survival gains and health care cost savings associated with nationwide implementation of evidence-based tobacco treatment for US patients with cancer and survivors. METHODS We developed a population-based dynamic survival and cost model including 18 million US cancer survivors, assuming 11.4% smoking prevalence, and 2 million annual incident cancer cases, assuming 15% smoking prevalence. The model tracked annual transitions among smoking, abstinence, relapse, survival, and death over 10 years, using proportional hazards survival mapping, explicit relapse dynamics, and 3% annual cost discounting. The primary comprehensive program scenario assumed 50% program reach, 45% abstinence among reached patients, a mortality hazard ratio of 0.79 for abstainers versus continuing smokers, and 20% annual relapse. Implementation scenarios and probabilistic sensitivity analyses were evaluated. RESULTS The comprehensive program scenario was projected to prevent 66,462 deaths and yield 287,446 life-years gained over 10 years, with $12.32 billion US dollars (USD) in present-value (PV) health care cost savings. In probabilistic sensitivity analysis with 10,000 simulations, mean outcomes were 66,542 lives saved (95% uncertainty interval [UI], 28,394 to 116,297) and $12.38 billion USD in PV cost savings (95% UI, $6.95 to $20.69 billion USD). An enhanced implementation scenario with 80% reach and 60% abstinence was projected to prevent 141,785 deaths, yield 613,219 life-years gained, and save $26.28 billion USD. Reach, abstinence, and relapse were the primary drivers of survival and economic value. The break-even program cost per participant was approximately $5,255 USD. CONCLUSION National implementation of evidence-based tobacco treatment in cancer care could save tens of thousands of lives and substantially reduce health care costs within 10 years.
No takes yet. Share an insight, caveat, or question.
Kypriotakis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: